{"ticker": {"uuid": "9eb4339c-80ff-46fe-8804-17d391f8d74c", "symbol": "INAB", "name": "In8bio\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 FWB:6JH0", "summary": "The article focuses on the \"Enterprise value to EBIT forward\" metric for IN8bio, Inc. (FWB:6JH0) on the Frankfurt Stock Exchange. It appears to be a financial data point provided by TradingView, possibly showing the value and change over a period.", "url": "https://www.tradingview.com/symbols/FWB-6JH0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T18:11:39", "published_display": "13 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 DUS:6JH0", "summary": "The article focuses on the \"Enterprise value to EBIT forward\" metric for IN8bio, Inc. (DUS:6JH0), listed on the Dusseldorf Stock Exchange. It provides a financial overview of the company's valuation, indicating market status as closed with no recent trades. The content primarily ", "url": "https://www.tradingview.com/symbols/DUS-6JH0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T18:10:32", "published_display": "13 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of IN8bio, Inc. \u2013 DUS:6JH0", "summary": "This article provides the \"Price to sales forward\" metric for IN8bio, Inc. (DUS:6JH0) on the Dusseldorf Stock Exchange. It indicates that the market is closed with no trades recorded at the time of publication, and the content is primarily a data placeholder from TradingView.", "url": "https://www.tradingview.com/symbols/DUS-6JH0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T12:40:56", "published_display": "13 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IN8bio publishes phase 1 glioblastoma trial results in JCO By Investing.com", "summary": "IN8bio, Inc. (NASDAQ:INAB) announced the publication of clinical data from its Phase 1 trial of INB-200 for glioblastoma in The Journal of Clinical Oncology. Despite a 41% year-to-date decline in stock value, InvestingPro analysis suggests the clinical-stage biotech, with a marke", "url": "https://uk.investing.com/news/stock-market-news/in8bio-publishes-phase-1-glioblastoma-trial-results-in-jco-93CH-4763927", "source_name": "Investing.com UK", "published_at": "2026-07-12T07:40:57", "published_display": "12 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx\u2122 DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma", "summary": "IN8bio announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology (JCO). The study demonstrates that their DeltEx\u2122 DRI doubles progression-free survival in newly diagnosed glioblastoma patients without significan", "url": "https://finance.yahoo.com/healthcare/articles/in8bio-announces-publication-journal-clinical-120000441.html", "source_name": "Market source", "published_at": "2026-07-09T16:40:45", "published_display": "09 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio publishes phase 1 glioblastoma trial results in JCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNbFNGMUdXT1ZLUXF1dmJvTDhHb1FMcEx1dlJoTjk0QktHc3puYjZIbDFDQ3I0R2wxLV9iRkllajJRVGpiRWFuZkhabGp0V1FHVThuRWtxUU04U19QMWFCVFB2bDMzMEJOMExLRzZnMTRrY2kyalYwZkR0WVNlekVrdHFuZVRBQlZ1RGdpSkh2c2c1NFY0TENLUWxMdWNCWUY1ZzZ2bkM1ZFlTV3dhNXlOOUF5blJJUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T13:23:08+00:00", "published_display": "09 Jul 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Announces Publication in The Journal of Clinical", "summary": "IN8bio, Inc. announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology. The study demonstrated that its DeltEx\u2122 DRI (Drug Resistant Immunotherapy) treatment doubled progression-free survival in newly diagnosed g", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324728/0/en/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-deltex-dri-doubles-progression-free-survival-in-newly-diagnosed-glioblastoma.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T11:40:21", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio publication says brain tumor therapy doubled progression-free survival", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcnlENHRDQ0NJbF83TUJ3MmF5UzhReXhLUGtIckhSeHA3cE9nQV9KMDBEWG4tcGhzVFQxN2R6RlVfdjN5TUNDRlpVRkJJTHlBbk5paEtnT25UQ09PNm9OQWZJSXhFUl91cGNMRFRJdW8tMjVFQjRfZ081Uy04dFNpUG12MkE1Q01WX1ZsWkRsSnJlekhsaWNTUlhjYnVodnFTcWxaM012cDVCdmlIOGJtU0xqMXZkcnFVRlZj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc updates its immunotherapy pipeline as Nasdaq-listed biotech navigates clinical milestones", "summary": "IN8bio Inc, a Nasdaq-listed clinical-stage biotechnology company, is advancing its gamma-delta T cell immunotherapy programs for various cancers. The company is navigating clinical milestones, with investors closely watching upcoming trial readouts and regulatory developments. It", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-inc-updates-its-immunotherapy-pipeline-as-nasdaq-listed-biotech/69713788", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T11:41:08", "published_display": "07 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INAB - IN8bio Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for IN8bio Inc. (INAB). It details key financial metrics such as market cap, enterprise value, income, sales, per-share data, and various ratios, alongside insider ownership, institutional ownership, an", "url": "https://finviz.com/stock?t=INAB&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-05T03:11:02", "published_display": "05 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio stock centers on clinical programs. The Nasdaq listing stays the key anchor.", "summary": "IN8bio (INAB) is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer, with its stock trading on the Nasdaq Capital Market. The company's value is primarily driven by its clinical pipeline progress, trial milestones, and financing decisions ra", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-stock-centers-on-clinical-programs-the-nasdaq-listing-stays-the/69682487", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:39:07", "published_display": "03 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc. (INAB) Edges Higher as Biotech Sector Shows Renewed Interest - On Balance Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVXplR09zVFo3ZzBmejU5TENaUFhIZU0wVWRHUlg2ZkJOS2Z4Z0V0ck1HMlZnNDI0anUxUFMtSG1SRW5ONjdXYTV6LTBWTHNSRWZYTDBTUmhTUTBtQVB0RzN6RDBhY1ZKNWd0dzkxTjlRNloyM2NKUVlkdGdYUzRaOFl3R0REVzdxWFJuSVZ2RkN1QnJIRm5LdG1qMVV0akFXbl9tY1ZNenRUWmhSd3pnVw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T15:44:24+00:00", "published_display": "02 Jul 2026 15:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of IN8bio, Inc. \u2013 NASDAQ:INAB", "summary": "This page from TradingView displays financial data, specifically the Enterprise Value to EBITDA (forward) for IN8bio, Inc. (NASDAQ:INAB). The article indicates that there are no current trades and provides an overview of the company's financials for investors and analysts.", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T13:11:45", "published_display": "30 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INAB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for IN8bio, Inc. (INAB), including analyst price targets and predictions for 2027. It details the stock's current price, performance, volatility, market capitalization, and upcoming earnings report. The piece also includes frequently asked questio", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:09:18", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6JH0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for IN8bio, Inc. (6JH0) for 2027, based on analyst opinions. It includes information on the stock's historical performance, earnings reports, revenue, net income, employee count, and answers frequently asked questions about buying", "url": "https://www.tradingview.com/symbols/SWB-6JH0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:50", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio, Inc. Actuals & Estimates (NASDAQ:INAB)", "summary": "This article provides key financial data and analyst estimates for IN8bio, Inc. (NASDAQ:INAB), including its current stock price, recent performance declines, and future price forecasts. It details the company's financial results, such as recent earnings and revenue, market capit", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:50", "published_display": "26 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of IN8bio, Inc. \u2013 SWB:6JH0", "summary": "This article provides financial information for IN8bio, Inc. (SWB:6JH0), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is sourced from FactSet Research Systems Inc. and ICE Data Services.", "url": "https://www.tradingview.com/symbols/SWB-6JH0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:22", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio, Inc. Actuals & Estimates (FWB:6JH0)", "summary": "This article provides an overview of IN8bio, Inc. (FWB:6JH0) financials and analyst estimates, including price targets, historical highs and lows, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that IN8bio does not pay dividends ", "url": "https://www.tradingview.com/symbols/FWB-6JH0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:22", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio, Inc. Actuals & Estimates (SWB:6JH0)", "summary": "This article provides financial actuals and estimates for IN8bio, Inc. (SWB:6JH0), including income statement, balance sheet, and cash flow data, along with analyst price targets and future earnings expectations. It outlines key financial figures like earnings per share and reven", "url": "https://www.tradingview.com/symbols/SWB-6JH0/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T05:09:39", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of IN8bio, Inc. \u2013 NASDAQ:INAB", "summary": "This article focuses on the \"Price to book forward\" metric for IN8bio, Inc. (NASDAQ: INAB). It presents a data point within the context of the company's financial overview on the TradingView platform, with no other detailed information provided.", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:22", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 SWB:6JH0", "summary": "This article provides the enterprise value to EBIT forward for IN8bio, Inc. (SWB:6JH0) on the Stuttgart Stock Exchange. It indicates that the financial data is specifically for \"Enterprise value to EBIT forward\" for the company. The page also lists various general sections of the", "url": "https://www.tradingview.com/symbols/SWB-6JH0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:21", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of IN8bio, Inc. \u2013 NASDAQ:INAB", "summary": "This article provides the enterprise value to revenue forward for IN8bio, Inc. (NASDAQ: INAB). It appears to be a financial data snippet from TradingView, indicating the value and any changes for this specific ratio. No further details or analysis are present in the provided cont", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:21", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of IN8BIO, Inc. (INAB), focusing on its profitability and balance sheet. However, the analysis states that relevant financial data for profitability metrics such as cash and cash equivalents, total assets, total liabilities, free ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:25", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Institutional Confidence", "summary": "This article reports on the institutional confidence in IN8BIO, Inc. (INAB), detailing key institutional shareholdings and changes in their positions. It lists prominent investment groups and individuals, along with the number of shares held and the percentage change in their hol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:19", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for IN8BIO, Inc. (INAB), detailing analyst ratings, price targets, and past and future EPS expectations. Based on 4 analysts, the consensus rates INAB as a \"Buy\" with a target price of USD 7.00, suggesting a significant upside. The repor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:19", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for IN8BIO, Inc. (INAB), focusing on its PE, PB, P/S, and P/CF ratios. It highlights that relevant data for these valuation metrics have not yet been disclosed by the company. The stock is currently trading at $1.420 USD, up 2.90%.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:53", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for IN8BIO, Inc. (INAB) but states that relevant business segment and regional revenue data have not been disclosed by the company yet. Despite the lack of specific financial details, the page displays INAB's cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/revenue", "source_name": "TradingKey", "published_at": "2026-06-16T03:40:10", "published_display": "16 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026", "summary": "IN8bio presented updated clinical data at ASCO 2026 for its DeltEx DRI therapy in newly diagnosed glioblastoma, showing a median progression-free survival of 13.0 months and median overall survival exceeding 19.5 months in repeat-dose patients. These results significantly surpass", "url": "https://www.globenewswire.com/news-release/2026/6/1/3304354/0/en/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-newly-diagnosed-glioblastoma-at-asco-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T18:11:47", "published_display": "15 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc Stock (US45332Y1001): Analyst coverage and valuation in focus", "summary": "IN8bio Inc, a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer, is being evaluated by a niche group of Wall Street analysts and investors. Due to its pre-revenue status and early-stage pipeline, valuation is based on pipeline potential, tria", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-inc-stock-us45332y1001-analyst-coverage-and-valuation-in-focus/69544975", "source_name": "AD HOC NEWS", "published_at": "2026-06-15T13:39:28", "published_display": "15 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc stock (US45332Y1001): Q1 2026 update keeps focus on gamma-delta T?cell pipeline", "summary": "IN8bio Inc reported its Q1 2026 financial results, emphasizing progress in its gamma-delta T-cell oncology pipeline. The company, a clinical-stage biotechnology firm, focuses on developing immunotherapies for cancer, leveraging gamma-delta T cells to target tumors. The update hig", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-inc-stock-us45332y1001-q1-2026-update-keeps-focus-on-gamma-delta/69500347", "source_name": "AD HOC NEWS", "published_at": "2026-06-08T12:40:12", "published_display": "08 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNV0laQm9kNzlPem9NcVdzRkVDbm9BRkZMS2hfcVZNSEd6OThfa2xZdGJtdUJUWjZ1dThoQWxDVGc3T0lBZW1JX3Jta3c1WFotQnZKZ2JNOGxnT1ByZTZ2MzB0Yk5uRFF2Yk83NUh6RUpnRlZ3Y29ZRFFWMGh0c01UbzNaRTAtLUZEX2ZiaUJmTXprcEpVeXMw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy IN8bio (INAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1tbjJvemJsQURFOUdzMmVKbkxsdDNGMmJJUTZEN2syNGVuTkRBa1FfMTRvb1AxR2ptYV82Sk9ldFdPYy04T3A1akNjZUVGSmJzS0JTUGw3X250bjV4VVkwV3U0cmIxT2tMWmpzTQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/in8bio-announces-publication-nature-communications-123000273.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:30:00+00:00", "published_display": "03 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brain cancer trial: IN8bio therapy tops 19.5 months vs 13.2", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNX2FvcmJ0eThHbk5mckp1cG5IMEFTVlRYaVdERnd5SVNORkQ1QTJla0hkX3BJdG50ZHIxSUJZbVpzc1hRUDl6WUhudWQtTkFZMzlFajdQTzNMLWRLMG1ZWFB2QTEwS252OFZ3bEFOekphRy1QVjl3ajBfZVVFYWluVFlYaERZTmNhSGdCa2xua0JDTkpld0xMUlhQWnJVUkcyaHlXMkNHakN6aDBWOWpqUktvQ3dtR2xZWXBqVkRZdVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc. (INAB) Surges Over 8%: Breaking Through Key Levels with Strong Momentum - Last Point Resistance", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSHJIRHU3bnQ2WGhlWVA3REVXWGtfOGxFa1NNLVhMdFJVY0c2bldiMGt4QThWVTBPQl90RGg2Rk1OR0YtOHUwMjMtTkdOQTQzLUIwNDZGTTR2X2x2T0xKTzNObFpfcU9aN3lWbXpXY09Sa0Q0dndlY1g4WUZHVTZ5R19WdjFCaU5TRnEwRVVVeTFZbW5lVUhuVmszX21BMVczcUNSc3pIQ2I1eTl5Mll4cG5MT3BLZFctLXl0bg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc. (INAB) Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock Rises - New Analyst Coverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQM0l2V1JSb0NIdHBxV1lVdC0tazJDaU8zSzVnTWEwZW56QUd4RlhyMmRwZGlFWXNqcTRERUtscUl2eElxN2RDeGttMFN1RGdldXF6NThXTkhGMXZFTnJYZGc5WmNrU25MWVVPZnMxVXVxWkVfbGlKQ3VPN2VjdTR0SkZud0QwZlNKSnlOSUtxNTJVSk03U3AwUEMxV2RYakdCZ0xNNlpzMGQzbGxoWkZTVDV3Z2FBcmpPTXRVSFg1Yw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/in8bio-presents-translational-data-demonstrating-120000030.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPWFFFVHZpR0JMdWZyT3FKckVjcllfTGIxQjR2bW9JVVlzTENfaDdsRXBIRmM2bUNaZWhSMkdJYVd2UE5jQUliWlFVbElEYUhOM2xUN2EwTlFudzMyc1NDdWRwM2xVWDV3cElIQ1FsOVhncFpVMDhKR0Z3dTQyWDhLQTUwZDZFX0QySjJTbXhGcnJUamduN05KTC1va1JyM1UzaVhNU1hTUEFFNlZqcU9obEdiVGdtQXBzVE41NUJsWVEyV20xSFZNUXJlN25ycEx0eUNkT0R2SmlHWWpzQmoyQ1o3VmVOQ0YzNEE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/in8bio-showcase-next-generation-t-120000734.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:00:00+00:00", "published_display": "06 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IN8bio (INAB) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DLUJ3Y3doenBldTB1UHdLdUc1Z1lOWlVlc21zRDlrRnlObFNiWlRRV1IzZTRua1JwWDZRMGVrSk1PQTlmeW5pbFFxQmhfWUdpbnZ6aVNqSzExTEZzV3lvSDUwYVhZXzF3?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T18:58:37+00:00", "published_display": "09 Jul 2025 18:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In8Bio (INAB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wX284S0ZtRkZscXQtR0RQMGdlVVBYU2MxYTZVeU9JY3pldTIwenJsZnpSSmc0bVNQWWdBZ3FLVHdXQ25wRzd6MkJoVXQzLWZUWWtN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T18:02:59+00:00", "published_display": "24 Apr 2025 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio (INAB) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1UQ2o1ZUk4MFVXXzVuZklyVGJhZnhsc2RRUVZvV29VQWdDeFVlT2VwU2RpX2QzbDI5VTZsR3ptOEZENEJoNXBSNjdnQzZnR1p5alRtNV9YQ3NqVHRkUDlDbHIySFdydw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T17:56:42+00:00", "published_display": "11 May 2024 17:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Are IN8bio Stock Is Soaring More Than 100% Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQVmhQRmJydEZWMUFHT1FSWXphdEM5czFfcUxjLWxHSEQxTHp1bUUwbEpGd3IzelYxU0s0VTlDbEQ3bGJidVRPWXYweFJHRWZ2UUtveHlQRU5ONU5lMFlRZ2VEVW5sbHROc3lYd0JoTGtDbVFQODFXam56WUo1ZWg5Zg?oc=5", "source_name": "Market source", "published_at": "2023-04-24T07:00:00+00:00", "published_display": "24 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INAB Stock Price and Chart \u2014 NASDAQ:INAB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5YZVlqTThzNXI5SzcwM1hSZG9xUkM2YW5aU3dnSko0WlVGd3VnM0NPWW5WSVVZVGdZOWhIdlJ0enhEVk4yS0pZR2h3Rm9HRW85Ukd6alFOX0pSUjlu?oc=5", "source_name": "TradingView", "published_at": "2021-12-17T08:00:00+00:00", "published_display": "17 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 FWB:6JH0", "summary": "The article focuses on the \"Enterprise value to EBIT forward\" metric for IN8bio, Inc. (FWB:6JH0) on the Frankfurt Stock Exchange. It appears to be a financial data point provided by TradingView, possibly showing the value and change over a period.", "url": "https://www.tradingview.com/symbols/FWB-6JH0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T18:11:39", "published_display": "13 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 DUS:6JH0", "summary": "The article focuses on the \"Enterprise value to EBIT forward\" metric for IN8bio, Inc. (DUS:6JH0), listed on the Dusseldorf Stock Exchange. It provides a financial overview of the company's valuation, indicating market status as closed with no recent trades. The content primarily ", "url": "https://www.tradingview.com/symbols/DUS-6JH0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T18:10:32", "published_display": "13 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of IN8bio, Inc. \u2013 DUS:6JH0", "summary": "This article provides the \"Price to sales forward\" metric for IN8bio, Inc. (DUS:6JH0) on the Dusseldorf Stock Exchange. It indicates that the market is closed with no trades recorded at the time of publication, and the content is primarily a data placeholder from TradingView.", "url": "https://www.tradingview.com/symbols/DUS-6JH0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T12:40:56", "published_display": "13 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio publishes phase 1 glioblastoma trial results in JCO By Investing.com", "summary": "IN8bio, Inc. (NASDAQ:INAB) announced the publication of clinical data from its Phase 1 trial of INB-200 for glioblastoma in The Journal of Clinical Oncology. Despite a 41% year-to-date decline in stock value, InvestingPro analysis suggests the clinical-stage biotech, with a marke", "url": "https://uk.investing.com/news/stock-market-news/in8bio-publishes-phase-1-glioblastoma-trial-results-in-jco-93CH-4763927", "source_name": "Investing.com UK", "published_at": "2026-07-12T07:40:57", "published_display": "12 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx\u2122 DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma", "summary": "IN8bio announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology (JCO). The study demonstrates that their DeltEx\u2122 DRI doubles progression-free survival in newly diagnosed glioblastoma patients without significan", "url": "https://finance.yahoo.com/healthcare/articles/in8bio-announces-publication-journal-clinical-120000441.html", "source_name": "Market source", "published_at": "2026-07-09T16:40:45", "published_display": "09 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio publishes phase 1 glioblastoma trial results in JCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNbFNGMUdXT1ZLUXF1dmJvTDhHb1FMcEx1dlJoTjk0QktHc3puYjZIbDFDQ3I0R2wxLV9iRkllajJRVGpiRWFuZkhabGp0V1FHVThuRWtxUU04U19QMWFCVFB2bDMzMEJOMExLRzZnMTRrY2kyalYwZkR0WVNlekVrdHFuZVRBQlZ1RGdpSkh2c2c1NFY0TENLUWxMdWNCWUY1ZzZ2bkM1ZFlTV3dhNXlOOUF5blJJUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T13:23:08+00:00", "published_display": "09 Jul 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Announces Publication in The Journal of Clinical", "summary": "IN8bio, Inc. announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology. The study demonstrated that its DeltEx\u2122 DRI (Drug Resistant Immunotherapy) treatment doubled progression-free survival in newly diagnosed g", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324728/0/en/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-deltex-dri-doubles-progression-free-survival-in-newly-diagnosed-glioblastoma.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T11:40:21", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio publication says brain tumor therapy doubled progression-free survival", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcnlENHRDQ0NJbF83TUJ3MmF5UzhReXhLUGtIckhSeHA3cE9nQV9KMDBEWG4tcGhzVFQxN2R6RlVfdjN5TUNDRlpVRkJJTHlBbk5paEtnT25UQ09PNm9OQWZJSXhFUl91cGNMRFRJdW8tMjVFQjRfZ081Uy04dFNpUG12MkE1Q01WX1ZsWkRsSnJlekhsaWNTUlhjYnVodnFTcWxaM012cDVCdmlIOGJtU0xqMXZkcnFVRlZj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc updates its immunotherapy pipeline as Nasdaq-listed biotech navigates clinical milestones", "summary": "IN8bio Inc, a Nasdaq-listed clinical-stage biotechnology company, is advancing its gamma-delta T cell immunotherapy programs for various cancers. The company is navigating clinical milestones, with investors closely watching upcoming trial readouts and regulatory developments. It", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-inc-updates-its-immunotherapy-pipeline-as-nasdaq-listed-biotech/69713788", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T11:41:08", "published_display": "07 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INAB - IN8bio Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for IN8bio Inc. (INAB). It details key financial metrics such as market cap, enterprise value, income, sales, per-share data, and various ratios, alongside insider ownership, institutional ownership, an", "url": "https://finviz.com/stock?t=INAB&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-05T03:11:02", "published_display": "05 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio stock centers on clinical programs. The Nasdaq listing stays the key anchor.", "summary": "IN8bio (INAB) is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer, with its stock trading on the Nasdaq Capital Market. The company's value is primarily driven by its clinical pipeline progress, trial milestones, and financing decisions ra", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-stock-centers-on-clinical-programs-the-nasdaq-listing-stays-the/69682487", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:39:07", "published_display": "03 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc. (INAB) Edges Higher as Biotech Sector Shows Renewed Interest - On Balance Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVXplR09zVFo3ZzBmejU5TENaUFhIZU0wVWRHUlg2ZkJOS2Z4Z0V0ck1HMlZnNDI0anUxUFMtSG1SRW5ONjdXYTV6LTBWTHNSRWZYTDBTUmhTUTBtQVB0RzN6RDBhY1ZKNWd0dzkxTjlRNloyM2NKUVlkdGdYUzRaOFl3R0REVzdxWFJuSVZ2RkN1QnJIRm5LdG1qMVV0akFXbl9tY1ZNenRUWmhSd3pnVw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T15:44:24+00:00", "published_display": "02 Jul 2026 15:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of IN8bio, Inc. \u2013 NASDAQ:INAB", "summary": "This page from TradingView displays financial data, specifically the Enterprise Value to EBITDA (forward) for IN8bio, Inc. (NASDAQ:INAB). The article indicates that there are no current trades and provides an overview of the company's financials for investors and analysts.", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T13:11:45", "published_display": "30 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INAB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for IN8bio, Inc. (INAB), including analyst price targets and predictions for 2027. It details the stock's current price, performance, volatility, market capitalization, and upcoming earnings report. The piece also includes frequently asked questio", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:09:18", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6JH0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for IN8bio, Inc. (6JH0) for 2027, based on analyst opinions. It includes information on the stock's historical performance, earnings reports, revenue, net income, employee count, and answers frequently asked questions about buying", "url": "https://www.tradingview.com/symbols/SWB-6JH0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:50", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio, Inc. Actuals & Estimates (NASDAQ:INAB)", "summary": "This article provides key financial data and analyst estimates for IN8bio, Inc. (NASDAQ:INAB), including its current stock price, recent performance declines, and future price forecasts. It details the company's financial results, such as recent earnings and revenue, market capit", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:50", "published_display": "26 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of IN8bio, Inc. \u2013 SWB:6JH0", "summary": "This article provides financial information for IN8bio, Inc. (SWB:6JH0), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is sourced from FactSet Research Systems Inc. and ICE Data Services.", "url": "https://www.tradingview.com/symbols/SWB-6JH0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:22", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio, Inc. Actuals & Estimates (FWB:6JH0)", "summary": "This article provides an overview of IN8bio, Inc. (FWB:6JH0) financials and analyst estimates, including price targets, historical highs and lows, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that IN8bio does not pay dividends ", "url": "https://www.tradingview.com/symbols/FWB-6JH0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:22", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio, Inc. Actuals & Estimates (SWB:6JH0)", "summary": "This article provides financial actuals and estimates for IN8bio, Inc. (SWB:6JH0), including income statement, balance sheet, and cash flow data, along with analyst price targets and future earnings expectations. It outlines key financial figures like earnings per share and reven", "url": "https://www.tradingview.com/symbols/SWB-6JH0/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T05:09:39", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of IN8bio, Inc. \u2013 NASDAQ:INAB", "summary": "This article focuses on the \"Price to book forward\" metric for IN8bio, Inc. (NASDAQ: INAB). It presents a data point within the context of the company's financial overview on the TradingView platform, with no other detailed information provided.", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:22", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 SWB:6JH0", "summary": "This article provides the enterprise value to EBIT forward for IN8bio, Inc. (SWB:6JH0) on the Stuttgart Stock Exchange. It indicates that the financial data is specifically for \"Enterprise value to EBIT forward\" for the company. The page also lists various general sections of the", "url": "https://www.tradingview.com/symbols/SWB-6JH0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:21", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of IN8bio, Inc. \u2013 NASDAQ:INAB", "summary": "This article provides the enterprise value to revenue forward for IN8bio, Inc. (NASDAQ: INAB). It appears to be a financial data snippet from TradingView, indicating the value and any changes for this specific ratio. No further details or analysis are present in the provided cont", "url": "https://www.tradingview.com/symbols/NASDAQ-INAB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:21", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of IN8BIO, Inc. (INAB), focusing on its profitability and balance sheet. However, the analysis states that relevant financial data for profitability metrics such as cash and cash equivalents, total assets, total liabilities, free ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:25", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Institutional Confidence", "summary": "This article reports on the institutional confidence in IN8BIO, Inc. (INAB), detailing key institutional shareholdings and changes in their positions. It lists prominent investment groups and individuals, along with the number of shares held and the percentage change in their hol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:19", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for IN8BIO, Inc. (INAB), detailing analyst ratings, price targets, and past and future EPS expectations. Based on 4 analysts, the consensus rates INAB as a \"Buy\" with a target price of USD 7.00, suggesting a significant upside. The repor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:19", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for IN8BIO, Inc. (INAB), focusing on its PE, PB, P/S, and P/CF ratios. It highlights that relevant data for these valuation metrics have not yet been disclosed by the company. The stock is currently trading at $1.420 USD, up 2.90%.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:53", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8BIO, Inc. (INAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for IN8BIO, Inc. (INAB) but states that relevant business segment and regional revenue data have not been disclosed by the company yet. Despite the lack of specific financial details, the page displays INAB's cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inab/revenue", "source_name": "TradingKey", "published_at": "2026-06-16T03:40:10", "published_display": "16 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026", "summary": "IN8bio presented updated clinical data at ASCO 2026 for its DeltEx DRI therapy in newly diagnosed glioblastoma, showing a median progression-free survival of 13.0 months and median overall survival exceeding 19.5 months in repeat-dose patients. These results significantly surpass", "url": "https://www.globenewswire.com/news-release/2026/6/1/3304354/0/en/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-newly-diagnosed-glioblastoma-at-asco-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T18:11:47", "published_display": "15 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc Stock (US45332Y1001): Analyst coverage and valuation in focus", "summary": "IN8bio Inc, a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer, is being evaluated by a niche group of Wall Street analysts and investors. Due to its pre-revenue status and early-stage pipeline, valuation is based on pipeline potential, tria", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-inc-stock-us45332y1001-analyst-coverage-and-valuation-in-focus/69544975", "source_name": "AD HOC NEWS", "published_at": "2026-06-15T13:39:28", "published_display": "15 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc stock (US45332Y1001): Q1 2026 update keeps focus on gamma-delta T?cell pipeline", "summary": "IN8bio Inc reported its Q1 2026 financial results, emphasizing progress in its gamma-delta T-cell oncology pipeline. The company, a clinical-stage biotechnology firm, focuses on developing immunotherapies for cancer, leveraging gamma-delta T cells to target tumors. The update hig", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/in8bio-inc-stock-us45332y1001-q1-2026-update-keeps-focus-on-gamma-delta/69500347", "source_name": "AD HOC NEWS", "published_at": "2026-06-08T12:40:12", "published_display": "08 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNV0laQm9kNzlPem9NcVdzRkVDbm9BRkZMS2hfcVZNSEd6OThfa2xZdGJtdUJUWjZ1dThoQWxDVGc3T0lBZW1JX3Jta3c1WFotQnZKZ2JNOGxnT1ByZTZ2MzB0Yk5uRFF2Yk83NUh6RUpnRlZ3Y29ZRFFWMGh0c01UbzNaRTAtLUZEX2ZiaUJmTXprcEpVeXMw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy IN8bio (INAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1tbjJvemJsQURFOUdzMmVKbkxsdDNGMmJJUTZEN2syNGVuTkRBa1FfMTRvb1AxR2ptYV82Sk9ldFdPYy04T3A1akNjZUVGSmJzS0JTUGw3X250bjV4VVkwV3U0cmIxT2tMWmpzTQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/in8bio-announces-publication-nature-communications-123000273.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:30:00+00:00", "published_display": "03 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brain cancer trial: IN8bio therapy tops 19.5 months vs 13.2", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNX2FvcmJ0eThHbk5mckp1cG5IMEFTVlRYaVdERnd5SVNORkQ1QTJla0hkX3BJdG50ZHIxSUJZbVpzc1hRUDl6WUhudWQtTkFZMzlFajdQTzNMLWRLMG1ZWFB2QTEwS252OFZ3bEFOekphRy1QVjl3ajBfZVVFYWluVFlYaERZTmNhSGdCa2xua0JDTkpld0xMUlhQWnJVUkcyaHlXMkNHakN6aDBWOWpqUktvQ3dtR2xZWXBqVkRZdVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc. (INAB) Surges Over 8%: Breaking Through Key Levels with Strong Momentum - Last Point Resistance", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSHJIRHU3bnQ2WGhlWVA3REVXWGtfOGxFa1NNLVhMdFJVY0c2bldiMGt4QThWVTBPQl90RGg2Rk1OR0YtOHUwMjMtTkdOQTQzLUIwNDZGTTR2X2x2T0xKTzNObFpfcU9aN3lWbXpXY09Sa0Q0dndlY1g4WUZHVTZ5R19WdjFCaU5TRnEwRVVVeTFZbW5lVUhuVmszX21BMVczcUNSc3pIQ2I1eTl5Mll4cG5MT3BLZFctLXl0bg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Inc. (INAB) Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock Rises - New Analyst Coverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQM0l2V1JSb0NIdHBxV1lVdC0tazJDaU8zSzVnTWEwZW56QUd4RlhyMmRwZGlFWXNqcTRERUtscUl2eElxN2RDeGttMFN1RGdldXF6NThXTkhGMXZFTnJYZGc5WmNrU25MWVVPZnMxVXVxWkVfbGlKQ3VPN2VjdTR0SkZud0QwZlNKSnlOSUtxNTJVSk03U3AwUEMxV2RYakdCZ0xNNlpzMGQzbGxoWkZTVDV3Z2FBcmpPTXRVSFg1Yw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/in8bio-presents-translational-data-demonstrating-120000030.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPWFFFVHZpR0JMdWZyT3FKckVjcllfTGIxQjR2bW9JVVlzTENfaDdsRXBIRmM2bUNaZWhSMkdJYVd2UE5jQUliWlFVbElEYUhOM2xUN2EwTlFudzMyc1NDdWRwM2xVWDV3cElIQ1FsOVhncFpVMDhKR0Z3dTQyWDhLQTUwZDZFX0QySjJTbXhGcnJUamduN05KTC1va1JyM1UzaVhNU1hTUEFFNlZqcU9obEdiVGdtQXBzVE41NUJsWVEyV20xSFZNUXJlN25ycEx0eUNkT0R2SmlHWWpzQmoyQ1o3VmVOQ0YzNEE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/in8bio-showcase-next-generation-t-120000734.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:00:00+00:00", "published_display": "06 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio (INAB) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DLUJ3Y3doenBldTB1UHdLdUc1Z1lOWlVlc21zRDlrRnlObFNiWlRRV1IzZTRua1JwWDZRMGVrSk1PQTlmeW5pbFFxQmhfWUdpbnZ6aVNqSzExTEZzV3lvSDUwYVhZXzF3?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T18:58:37+00:00", "published_display": "09 Jul 2025 18:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In8Bio (INAB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wX284S0ZtRkZscXQtR0RQMGdlVVBYU2MxYTZVeU9JY3pldTIwenJsZnpSSmc0bVNQWWdBZ3FLVHdXQ25wRzd6MkJoVXQzLWZUWWtN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T18:02:59+00:00", "published_display": "24 Apr 2025 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IN8bio (INAB) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1UQ2o1ZUk4MFVXXzVuZklyVGJhZnhsc2RRUVZvV29VQWdDeFVlT2VwU2RpX2QzbDI5VTZsR3ptOEZENEJoNXBSNjdnQzZnR1p5alRtNV9YQ3NqVHRkUDlDbHIySFdydw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T17:56:42+00:00", "published_display": "11 May 2024 17:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Are IN8bio Stock Is Soaring More Than 100% Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQVmhQRmJydEZWMUFHT1FSWXphdEM5czFfcUxjLWxHSEQxTHp1bUUwbEpGd3IzelYxU0s0VTlDbEQ3bGJidVRPWXYweFJHRWZ2UUtveHlQRU5ONU5lMFlRZ2VEVW5sbHROc3lYd0JoTGtDbVFQODFXam56WUo1ZWg5Zg?oc=5", "source_name": "Market source", "published_at": "2023-04-24T07:00:00+00:00", "published_display": "24 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INAB Stock Price and Chart \u2014 NASDAQ:INAB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5YZVlqTThzNXI5SzcwM1hSZG9xUkM2YW5aU3dnSko0WlVGd3VnM0NPWW5WSVVZVGdZOWhIdlJ0enhEVk4yS0pZR2h3Rm9HRW85Ukd6alFOX0pSUjlu?oc=5", "source_name": "TradingView", "published_at": "2021-12-17T08:00:00+00:00", "published_display": "17 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 53, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 37, "score": 55, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 10.86, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 1.33, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": -7.0, "twelve_week_move": -11.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.370196, "market_dynamics_buy_signal": false, "relative_strength": -36.043259, "fair_value_gap": -90.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.6049, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, -7.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 15}, {"label": "Market source", "count": 9}, {"label": "GlobeNewswire", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "Stock Titan", "count": 3}, {"label": "AD HOC NEWS", "count": 3}, {"label": "dars.gov.et", "count": 3}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, -7.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBIT forward of IN8bio, Inc. \u2013 FWB:6JH0"}], "updated_at": "2026-07-22T11:15:11.287892+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}